Thoracic Malignancies Surgery

Dear Colleagues,

Innovation in medicine has been dramatically changing patients’ prognoses, constantly improving outcomes. Moreover, these changes have a profound impact on clinicians’ daily work with an increasingly rapid change in the standards of care. In more detail, in recent years, the role of thoracic surgeons has faced several challenges. From a technical point of view, the significant expansion of minimally invasive techniques requires, on one hand, maintaining the highest standard of oncological radicality, reducing the impact to a minimum, and on the other hand, pushing the boundaries of technologies with the robotic platforms that are increasingly becoming available and growing in popularity. Likewise, from a clinical point of view, the development of immunotherapies promises a radical modification of current indications. Indeed, the encouraging results of clinical trials that reveal a possible use of immunotherapies in early-stage malignancies and dramatic responses in advanced-stage patients suggest that surgery might be offered more frequently to advanced-stage cancers, and we might observe changes in indications for early-stage patients based on their molecular profile.

As a result, the role of the thoracic surgeon is expected to change. Still, the focus will still be on treating all thoracic malignancies but based on an increasingly multimodal approach.

We are pleased to invite you to contribute to this Special Issue focusing on the latest updates in the surgical treatment of thoracic malignancies. Articles should focus on novel surgical and interventional approaches or describe innovative techniques, report results of trials or studies, and outline rare presentations of thoracic cancer that required tailored treatments.

Manuscripts may focus on all thoracic malignancies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: thoracic surgery, interventional radiology, and interventional pulmonology.

We look forward to receiving your contributions.

You may choose our Joint Special Issue in Cancers.

Dr. Francesco Guerrera
Dr. Pietro Bertoglio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• non-small cell lung cancer
• thymoma
• mesothelioma
• esophageal cancer
• surgery
• minimally invasive surgery
• clinical trials
• new technologies
• immunotherapy